Will Doctors Who Are Spreading COVID-19 Misinformation Ever Face Penalty?
Earlier this month, Dr. Rashid Buttar posted on Twitter that COVID-19 “was a planned operation” and shared an article alleging that most people who got vaccinated against the coronavirus would be dead by 2025.
His tweets are a recent addition to a steady stream of spurious claims about the COVID-19 vaccines and treatments. Another example is Dr. Sherri Jane Tenpenny’s June testimony, before Ohio state legislators, that the vaccine could cause people to become magnetized. Clips from the hearing went viral on the internet. Earlier in the pandemic, on April 9, 2020, Dr. Joseph Mercola posted a video about wh...
Source: TIME: Health - September 20, 2021 Category: Consumer Health News Authors: Victoria Knight / Kaiser Health News Tags: Uncategorized COVID-19 Source Type: news
New Data on RYBREVANT ® (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary results from the Phase 1b CHRYSALIS-2 (NCT04077463) study evaluating RYBREVANT® (amivantamab-vmjw) in combination with lazertinib in the treatment of patients with non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib and platinum chemotherapy.[i] While previously reported results have demonstrated durable responses with RYBREVANT® in combination with lazertini...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
RYBREVANT ® (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new analysis from the CHRYSALIS (NCT02609776) study evaluating RYBREVANT® (amivantamab-vmjw) monotherapy and a combination regimen with lazertinib in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations who progressed after osimertinib.[1] The analysis showed higher activity and longer duration of response (DOR) in patients treated with the combination therapy, demonstrating the potential benefit of targeting the extracellular (outer) and catalytic (i...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Could gene editing chickens prevent future pandemics?
Rearing virus-resistant birds could benefit humans too, say scientists, and Covid may have made us more open to the controversial technologyDiseases such as avian flu trigger the culling of millions of birds each year. But that need not be the case for much longer.Vaccines are one preventive strategy employed in some countries, but they do not stop birds from being infected, getting mild versions of the disease and transmitting it to healthy chickens. In fact, this imperfect shield can make things worse, incentivising the virus to mutate to evade the vaccine.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - September 18, 2021 Category: Science Authors: Natalie Grover Tags: Gene editing Bird flu Environment Health Society Coronavirus Infectious diseases Medical research Science Chicken Food World news Animals Source Type: news
Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA ® (erdafitinib) in Combination with Cetrelimab, a PD-1 Inhibitor
September 17, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1b/2 NORSE (NCT03473743) study evaluating BALVERSA® (erdafitinib) in combination with cetrelimab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, compared to BALVERSA® monotherapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) with fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations who are ineligible for cisplatin, a current standard of care treatment for mUC. The results were highlighted in an oral presentation at t...
Source: Johnson and Johnson - September 17, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Ivermectin: Cochrane ’s most talked about review so far, ever. Why?
In this author interview with Stephanie Weibel and Maria Popp, we find out more about their Cochrane review, Ivermectin for treating and preventing COVID-19. The review currently has an Altmetric Attention Score of more than 7000, which makes it the most talked-about review in the history of the Cochrane Library.Briefly, what is Ivermectin?Ivermectin is a medicine used to kill parasites, such as intestinal worms (helminths) in animals or scabies in humans. It is inexpensive and it is widely used in regions of the world where parasitic infestations are common, such as in parts of Asia and South America. Ivermectin has few u...
Source: Cochrane News and Events - September 14, 2021 Category: Information Technology Authors: Lydia Parsonson Source Type: news
Bite injuries among vaccination staff participating in a mass canine rabies vaccination campaign, Haiti 2016-2017 - Kirkhope RT, Gibson AD, Augustin PD, Crowdis K, F énelon N, MacLeod ET, Vigilato MAN, Pieracci EG, Wallace RM.
Elimination of dog-transmitted human rabies worldwide will require large-scale dog vaccination campaigns. However, this places participating vaccinators at increased risk. Data from the 2016-2017 Haitian mass rabies vaccination campaign was analyzed to det... (Source: SafetyLit)
Source: SafetyLit - September 12, 2021 Category: International Medicine & Public Health Tags: Non-Human Animals and Insects Source Type: news
Brookfield Zoo Vaccinating Animals Against COVID-19 Brookfield Zoo Vaccinating Animals Against COVID-19
Animals at Brookfield Zoo in suburban Chicago are getting their own COVID-19 vaccinations.Associated Press (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - September 8, 2021 Category: Intensive Care Tags: Infectious Diseases News Source Type: news
Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
South Africa: MEC Ivan Meyer Joins Veterinary Services Officials During Rabies Vaccination Campaign in Klapmuts
[Govt of SA] Free animal health care makes a difference in the fight against rabies (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - September 7, 2021 Category: African Health Source Type: news
A human is not a horse. So why is a livestock drug sweeping America? | Arwa Mahdawi
There is scant evidence that ivermectin can treat or prevent Covid - but that hasn ’t stopped rightwing pundits and conservative politicians from promoting itYou arenot a horse. You are not a cow. You are, I ’m afraid, a homo sapiens living in a world so deranged that people would rather poison themselves with worm medicine meant for farm animals than take a vaccine meant for human beings.Related:Australian imports of ivermectin increase tenfold, prompting warning from TGAContinue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - August 31, 2021 Category: Science Authors: Arwa Mahdawi Tags: Health Science Life and style Coronavirus World news US news Animals Infectious diseases Source Type: news
Janssen Presents Phase 1 Results for RYBREVANTTM (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
August 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANTTM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations. The initial data showed anti-tumor activity in patients with METex14 mutations and a safety profile consistent with reported experience at the approved CHRYSALIS Phase 2 dose (RYBREVANTTM 1050 mg [<80 kg] / 1400 mg [≥80 kg]).[1] These findings will be featured at th...
Source: Johnson and Johnson - August 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
GSK and CureVac’s second vaccine yields stronger response
Results of animal study shows success in tackling several coronavirus variants (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - August 16, 2021 Category: Pharmaceuticals Source Type: news
GSK and CureVac’s second Covid vaccine yields stronger response
Results of animal study show success in tackling several coronavirus variants (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - August 16, 2021 Category: Pharmaceuticals Source Type: news
Coronavirus latest: Second GSK/CureVac vaccine shows promise in animal trial
(Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - August 16, 2021 Category: Pharmaceuticals Source Type: news
